

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants:	Elfi Biedermann, et al.	Examiner:	Benjamin J. Packard
Serial No:	10/509,362	Art Unit:	4173
Filed:	April 15, 2005	Docket:	21371
For:	USE OF PYRIDYL AMIDES AS INHIBITORS OF ANGIOGENESIS	Dated:	April 25, 2008

Confirmation No.: 3950

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

**REQUEST FOR RECONSIDERATION OF RESTRICTION REQUIREMENT AND
SPECIES ELECTION UNDER 37 C.F.R. §1.475(b)**


Sir:

In response to the Official Action dated October 26, 2007, applicants provisionally elect, with traverse, pursuant to the imposed restriction requirement, Group I, drawn to a method of inhibiting or reducing angiogenesis in a mammal, which is encompassed by Claims 15-26 and 29-30, and further provisionally elects, with traverse, N-[4-(1-benzoyl-piperidin-4-yl)-butyl]-3-(pyridin-3-yl)-acrylamide as listed in Claim 22 and further provisionally elects, with traverse, inflammatory disorder as a specific disease of Claim 24 for prosecution on the merits in this application.

CERTIFICATE OF ELECTRONIC FILING

I hereby certify that this correspondence is being deposited with the United States Patent & Trademark Office via Electronic Filing through the United States Patent and Trademark Office e-business website.

Dated: April 25, 2008



Peter I. Bernstein